StockData
Adaptive Biotechnologies Corp logo

Adaptive Biotechnologies Corp (ADPT) stock

ADPTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 12/30
$28.49+0.62 (+2.22%)

Close on Nov 17, 2026Market cap $4.55BP/E –Yield –

Adaptive Biotechnologies price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Adaptive Biotechnologies's price to sales ratio was 15.5× on Nov 11, 2026, against 11.9× a year earlier. Over the last 5 years it ranged from 2.2× to 27.0×, with a median of 7.2×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202615.5×+5.7
2025Dec 31, 20259.8×+4.8
2024Dec 31, 20245.0×+1.0
2023Dec 29, 20233.9×−2.6
2022Dec 30, 20226.5×−20.5
2021Dec 31, 202127.0×−60.3
2020Dec 31, 202087.3×+39.6
2019Dec 31, 201947.7×–

More Adaptive Biotechnologies figures

See a number that looks wrong?